
Currently out of the existing stock ratings of Rudy Li, 1 are a HOLD (3.33%), 29 are a BUY (96.67%).
Analyst Rudy Li, currently employed at WOLFE, has had 65.48% of price targets met with an average potential upside of 69.59%, reached in 141 days on average. Previously, Rudy Li worked at LEERINK.
Rudy Li has documented 59 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CNTA, Centessa Pharmaceuticals PLC ADR at 31-Mar-2026.
Analyst best performing recommendations are on XENE (XENON PHARMACEUTICALS).
The best stock recommendation documented was for XENE (XENON PHARMACEUTICALS) on 2/24/2026. The price target of $60 was fulfilled within 13 days with a profit of $15.21 (33.96%), with a performance score of 26.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Aug-2026
$40
$13.19 (49.20%)
$25
3 months 1 days ago
(21-Aug-2026)
4/6 (66.67%)
$7.71 (23.88%)
237
Buy Since 08-Nov-2021
$40
$13.19 (49.20%)
$38
3 months 18 days ago
(04-Aug-2026)
7/11 (63.64%)
$8.33 (26.30%)
97
Buy Since 26-Apr-2023
$58
$31.19 (116.34%)
$60
3 months 18 days ago
(04-Aug-2026)
6/8 (75%)
$26.33 (83.14%)
453
Buy Since 05-Jan-2026
$35
$8.19 (30.55%)
$35
3 months 18 days ago
(04-Aug-2026)
2/3 (66.67%)
$3.33 (10.51%)
12
Buy Since 12-Nov-2019
$39
$12.19 (45.47%)
$39
6 months 11 days ago
(11-May-2026)
4/7 (57.14%)
$6.36 (19.49%)
398
What Year was the first public recommendation made by Rudy Li?